AIDDISON logo

AIDDISON

by MilliporeSigmasigmaaldrich.com
VISIT OFFICIAL WEBSITE →
Disclaimer: This page is an independent third-party listing and is not affiliated with, sponsored by, or endorsed by AIDDISON or MilliporeSigma. All product names, logos, and brands are property of their respective owners.

OVERVIEW

AI-powered drug discovery SaaS platform combining generative AI, machine learning, and CADD to accelerate hit identification and lead optimization.

AIDDISON™ is a secure, web-based Software-as-a-Service (SaaS) platform developed by MilliporeSigma (the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany) to revolutionize the small molecule drug discovery process. It acts as a comprehensive, 'one-stop-shop' for medicinal chemists by seamlessly integrating Artificial Intelligence (AI), Machine Learning (ML), and advanced 3D Computer-Aided Drug Design (CADD) techniques .

Key Capabilities and Benefits:

  • AI-Powered Design & Screening: The platform leverages generative AI models (based on REINVENT) to explore unbounded chemical space and design novel small-molecule libraries with optimized structural and ADMET properties . It can virtually screen compounds from a universe of over 60 billion chemical targets, significantly enhancing the efficiency of virtual screening and in-silico lead discovery .
  • Data Advantage: AIDDISON™ is the first commercially available product that includes ML models trained on proprietary, experimentally generated datasets from pharmaceutical R&D, ensuring scientifically valid and reliable predictions . It also incorporates ADME/Tox ML models trained on decades of preclinical data to help reduce development cycles .
  • Synthesis Integration: A major differentiator is the seamless API integration with SYNTHIA™ retrosynthesis software . This connection provides an immediate Synthetic Accessibility (SA) score and proposes synthesis routes, bridging the gap between virtual design and real-world manufacturability .
  • User Experience: The platform is designed with an intuitive, web-based interface to lower the barrier to entry, enabling less computationally sophisticated medicinal chemists to utilize powerful AI/ML and CADD tools in their daily activities .

Target Users and Use Cases:

  • Target Users: Medicinal Chemists, Computational Chemists, Drug Designers, and R&D teams in biotech, pharma, and academia .
  • Use Cases: Hit Identification, Lead Optimization, Scaffold Hopping, Ligand-based and Structure-based Screening, and Synthesis Planning .

RATING & STATS

Founded
2023

KEY FEATURES

  • Generative AI Molecule Design (De Novo Design)
  • Virtual Screening (>60 billion chemical targets)
  • Predictive ADME/Tox Modeling
  • Synthetic Accessibility Scoring (via SYNTHIA™)
  • Ligand-based and Structure-based Drug Design
  • Molecular Docking and Shape-based Alignment
  • Trained on proprietary pharmaceutical R&D data

PRICING

Model: subscription
Contact MilliporeSigma for a quote. Subscription model designed for small teams, academic users, and enterprise. A free trial is available.
FREE TRIAL

TECHNICAL DETAILS

Deployment: cloud, saas
Platforms: web
🔌 API Available

USE CASES

Hit Identification and Lead OptimizationIn-silico Drug DiscoveryScaffold HoppingSynthesis Planning and Reagent Recommendation

INTEGRATIONS

SYNTHIA™ Retrosynthesis SoftwareBioSolveIT (FTrees)Cresset (Flare, pyFlare)RDKitGOSTAR® Databases

COMPLIANCE & SECURITY

Compliance:
ISO 27001
Security Features:
  • 🔒ISO 27001 Certified Security
  • 🔒Data and IP Protection
  • 🔒Cloud-Native Security

SUPPORT & IMPLEMENTATION

Support: email, contact form
Target Company Size: startup, small, medium, enterprise
TRAINING AVAILABLE

PROS & CONS

✓ Pros:
  • +Seamless integration of AI/ML, CADD, and synthesis planning (SYNTHIA™)
  • +Trained on proprietary, experimentally validated pharmaceutical R&D datasets
  • +Intuitive, web-based SaaS interface for non-computational experts
  • +Ability to search and generate molecules in vast chemical space (>60 billion)
✗ Cons:
  • -Pricing not publicly disclosed (Enterprise model)
  • -Relatively new product (Launched Dec 2023)
  • -Requires contact for demo/pricing

TRY IT OUT

ABOUT MILLIPORESIGMA